MedTrace Logo

CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices

NCT03217331 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-06-25

No results posted yet for this study

Summary

This is a Phase 1b/IIa, single centre, non-randomised open-label uncontrolled study to assess safety, effect and PK of oral CRD-102 in patients with RHF associated with the presence of an LVAD.

Conditions

  • Right Heart Failure
  • Left Ventricular Assist Device

Interventions

DRUG

CRD-102

14 mg CRD-102 capsules administered twice daily orally for 14 days.

Sponsors & Collaborators

  • Cardiora Pty. Ltd.

    lead INDUSTRY

Principal Investigators

  • David Kaye, MD PhD · Cardiora Pty. Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-06
Primary Completion
2018-10-10
Completion
2019-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03217331 on ClinicalTrials.gov